537 related articles for article (PubMed ID: 11032210)
21. Recommendations for the registration of agents to be used in the prevention and treatment of glucocorticoid-induced osteoporosis: updated recommendations from the Group for the Respect of Ethics and Excellence in Science.
Abadie EC; Devogealer JP; Ringe JD; Ethgen DJ; Bouvenot GM; Kreutz G; Laslop A; Orloff JJ; Vanderauwera PM; Delmas PD; Dere WH; Branco J; Altman RD; Avouac BP; Menkes CJ; Vanhaelst L; Mitlak BH; Tsouderos Y; Reginster JY
Semin Arthritis Rheum; 2005 Aug; 35(1):1-4. PubMed ID: 16084217
[TBL] [Abstract][Full Text] [Related]
22. [New development in bisphosphonate treatment. Bisphosphonates for the treatment of glucocorticoid-induced osteoporosis].
Soen S
Clin Calcium; 2009 Jan; 19(1):44-53. PubMed ID: 19122264
[TBL] [Abstract][Full Text] [Related]
23. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
25. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
26. [Goals of treatment for osteoporosis].
Nakamura T
Clin Calcium; 2008 Oct; 18(10):1389-95. PubMed ID: 18830034
[TBL] [Abstract][Full Text] [Related]
27. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?
Bonnick SL; Shulman L
Am J Med; 2006 Apr; 119(4 Suppl 1):S25-31. PubMed ID: 16563938
[TBL] [Abstract][Full Text] [Related]
28. [Glucocorticoid-induced osteoporosis].
Tóth M; Tulassay Z
Orv Hetil; 2000 Jan; 141(5):219-23. PubMed ID: 10697979
[TBL] [Abstract][Full Text] [Related]
29. Bisphosphonates: safety and efficacy in the treatment and prevention of osteoporosis.
Greenspan SL; Harris ST; Bone H; Miller PD; Orwoll ES; Watts NB; Rosen CJ
Am Fam Physician; 2000 May; 61(9):2731-6. PubMed ID: 10821153
[TBL] [Abstract][Full Text] [Related]
30. [Glucocorticoid-induced osteoporosis : treatment update].
Soen S
Clin Calcium; 2012 Feb; 22(2):229-35. PubMed ID: 22298077
[TBL] [Abstract][Full Text] [Related]
31. [Use of bisphosphates in treatment of primary and secondary osteoporosis].
Olszyński WP
Pol Tyg Lek; 1995 Nov; 50(44-47):56-8. PubMed ID: 8643431
[TBL] [Abstract][Full Text] [Related]
32. The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression.
Amin S; Lavalley MP; Simms RW; Felson DT
J Bone Miner Res; 2002 Aug; 17(8):1512-26. PubMed ID: 12162505
[TBL] [Abstract][Full Text] [Related]
33. Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial.
Mok CC; Ho LY; Ma KM
Bone; 2015 Jun; 75():222-8. PubMed ID: 25761434
[TBL] [Abstract][Full Text] [Related]
34. Bisphosphonates for osteoporosis in people with cystic fibrosis.
Conwell LS; Chang AB
Cochrane Database Syst Rev; 2012 Apr; (4):CD002010. PubMed ID: 22513903
[TBL] [Abstract][Full Text] [Related]
35. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.
Brown JP; Josse RG;
CMAJ; 2002 Nov; 167(10 Suppl):S1-34. PubMed ID: 12427685
[TBL] [Abstract][Full Text] [Related]
36. A metaanalysis on the use of bisphosphonates in corticosteroid induced osteoporosis.
Homik JE; Cranney A; Shea B; Tugwell P; Wells G; Adachi JD; Suarez-Almazor ME
J Rheumatol; 1999 May; 26(5):1148-57. PubMed ID: 10332982
[TBL] [Abstract][Full Text] [Related]
37. Bisphosphonates for steroid induced osteoporosis.
Homik J; Cranney A; Shea B; Tugwell P; Wells G; Adachi R; Suarez-Almazor M
Cochrane Database Syst Rev; 2000; (2):CD001347. PubMed ID: 10796432
[TBL] [Abstract][Full Text] [Related]
38. The effects of corticosteroids on bone growth and bone density.
Weldon D
Ann Allergy Asthma Immunol; 2009 Jul; 103(1):3-11; quiz 11-3, 50. PubMed ID: 19663120
[TBL] [Abstract][Full Text] [Related]
39. [Secondary osteoporosis UPDATE. Clinical significance of glucocorticoid-induced osteoporosis].
Suzuki Y; Sato S
Clin Calcium; 2010 May; 20(5):645-53. PubMed ID: 20445275
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of bisphosphonates in management of low bone density in inflammatory bowel disease: A meta-analysis.
Yao L; Wang H; Dong W; Liu Z; Mao H
Medicine (Baltimore); 2017 Jan; 96(3):e5861. PubMed ID: 28099343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
